

Adolescent and Young Adult Committee

Friday, September 19 • 4:15 – 5:45 PM CT
Toronto (Ballroom Level)

Agenda

- A. Welcome**
Becky Johnson, MD
- B. ALTE213: Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults with Cancer**
Becky Johnson, MD
- C. AREN1721, a Randomized Phase 2 Trial of Axitinib+Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/translocation Renal Cell Carcinoma (tRCC) Across All Age Groups**
Mamta Parikh, MD
- D. ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy**
Etan Orgel, MD
- E. Addressing Financial Toxicity in AYAs with Cancer**
Melissa Beauchemin, PhD
- F. Patient Advocate Perspectives: Life with advanced cancer**
JJ Singleton & Valerie Fraser
- G. Goals of Care at End of Life for AYAs with Cancer**
Rosemarie Mastropolo, MD
- H. Q&A and Discussion**